Gilead Sciences Stock Buy Hold or Sell Recommendation
| GILD Stock | USD 92.41 1.06 1.16% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Gilead Sciences is 'Buy'. Macroaxis provides Gilead Sciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GILD positions.
Check out Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide. Note, we conduct extensive research on individual companies such as Gilead and provide practical buy, sell, or hold advice based on investors' constraints. Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Gilead |
Execute Gilead Sciences Buy or Sell Advice
The Gilead recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Gilead Sciences. Macroaxis does not own or have any residual interests in Gilead Sciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Gilead Sciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Gilead Sciences Trading Alerts and Improvement Suggestions
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More |
Gilead Sciences Returns Distribution Density
The distribution of Gilead Sciences' historical returns is an attempt to chart the uncertainty of Gilead Sciences' future price movements. The chart of the probability distribution of Gilead Sciences daily returns describes the distribution of returns around its average expected value. We use Gilead Sciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Gilead Sciences returns is essential to provide solid investment advice for Gilead Sciences.
| Mean Return | 0.28 | Value At Risk | -1.82 | Potential Upside | 2.17 | Standard Deviation | 1.41 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Gilead Sciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Gilead Stock Institutional Investors
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 14.1 M | Northern Trust Corp | 2024-09-30 | 12.5 M | Legal & General Group Plc | 2024-06-30 | 12.4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 11.7 M | Amundi | 2024-06-30 | 11.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 10.6 M | Amvescap Plc. | 2024-06-30 | 10.1 M | Goldman Sachs Group Inc | 2024-06-30 | 9.2 M | Pacer Advisors, Inc. | 2024-06-30 | 7.9 M | Blackrock Inc | 2024-06-30 | 120.6 M | Vanguard Group Inc | 2024-09-30 | 115.3 M |
Gilead Sciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (6.3B) | (5.6B) | (659M) | 74M | 673M | 706.7M | |
| Free Cash Flow | 8.3B | 7.5B | 10.8B | 8.3B | 7.4B | 4.2B | |
| Depreciation | 1.4B | 1.5B | 2.1B | 2.1B | 2.7B | 2.8B | |
| Other Non Cash Items | 4.6B | 7.8B | 2.1B | 5.1B | 2.2B | 2.3B | |
| Capital Expenditures | 825M | 650M | 579M | 728M | 585M | 614.3M | |
| Net Income | 5.4B | 89M | 6.2B | 4.6B | 5.6B | 3.0B | |
| End Period Cash Flow | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.7B | |
| Change To Inventory | (310M) | (95M) | (195M) | 11M | (842M) | (799.9M) | |
| Change To Netincome | (478M) | 6.5B | 11.4B | 3.5B | 4.0B | 4.2B | |
| Investments | (2.3B) | 11.9B | (3.1B) | (2.5B) | (1.9B) | (1.8B) | |
| Change Receivables | (218M) | (1.2B) | 313M | (406M) | (466.9M) | (490.2M) | |
| Net Borrowings | (2.8B) | 5.7B | (4.8B) | (1.5B) | (1.4B) | (1.3B) | |
| Dividends Paid | 3.2B | 3.4B | 3.6B | 3.7B | 3.8B | 3.4B |
Gilead Sciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Gilead Sciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Gilead Sciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Gilead stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.22 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 1.42 | |
Ir | Information ratio | 0.11 |
Gilead Sciences Volatility Alert
Gilead Sciences has relatively low volatility with skewness of 1.01 and kurtosis of 7.18. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Gilead Sciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Gilead Sciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Gilead Sciences Fundamentals Vs Peers
Comparing Gilead Sciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Gilead Sciences' direct or indirect competition across all of the common fundamentals between Gilead Sciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Gilead Sciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Gilead Sciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Gilead Sciences to competition |
| Fundamentals | Gilead Sciences | Peer Average |
| Return On Equity | 0.0056 | -0.31 |
| Return On Asset | 0.12 | -0.14 |
| Profit Margin | 0 % | (1.27) % |
| Operating Margin | 0.42 % | (5.51) % |
| Current Valuation | 132.06 B | 16.62 B |
| Shares Outstanding | 1.25 B | 571.82 M |
| Shares Owned By Insiders | 0.11 % | 10.09 % |
| Shares Owned By Institutions | 88.34 % | 39.21 % |
| Number Of Shares Shorted | 17.74 M | 4.71 M |
| Price To Earning | 359.42 X | 28.72 X |
| Price To Book | 6.16 X | 9.51 X |
| Price To Sales | 4.02 X | 11.42 X |
| Revenue | 27.12 B | 9.43 B |
| Gross Profit | 21.62 B | 27.38 B |
| EBITDA | 7.61 B | 3.9 B |
| Net Income | 5.61 B | 570.98 M |
| Cash And Equivalents | 6.14 B | 2.7 B |
| Cash Per Share | 4.90 X | 5.01 X |
| Total Debt | 24.99 B | 5.32 B |
| Debt To Equity | 1.30 % | 48.70 % |
| Current Ratio | 1.43 X | 2.16 X |
| Book Value Per Share | 14.83 X | 1.93 K |
| Cash Flow From Operations | 8.01 B | 971.22 M |
| Short Ratio | 2.65 X | 4.00 X |
| Earnings Per Share | 0.09 X | 3.12 X |
| Price To Earnings To Growth | 0.53 X | 4.89 X |
| Target Price | 97.2 | |
| Number Of Employees | 18 K | 18.84 K |
| Beta | 0.19 | -0.15 |
| Market Capitalization | 113.85 B | 19.03 B |
| Total Asset | 62.12 B | 29.47 B |
| Retained Earnings | 16.3 B | 9.33 B |
| Working Capital | 4.8 B | 1.48 B |
Note: Disposition of 3025 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3 [view details]
Gilead Sciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Gilead . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Gilead Sciences Buy or Sell Advice
When is the right time to buy or sell Gilead Sciences? Buying financial instruments such as Gilead Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Apparel Thematic Idea Now
Apparel
Companies manufacturing textile accessories and apparel products. The Apparel theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Apparel Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.